INTANGIBLE ASSETS (Tables)

3 Months Ended

Mar. 31, 2017

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Schedule of intangible assets

The following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of March 31, 2017 and December 31, 2016:

	March 31, 2017
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted- Average Remaining Amortization Period (yrs.)
Amortizing intangible assets:
OPERA® software patent	$	31,951	$	(6,989	)	$	24,962		12.5
Development costs of corporate website		91,743		(91,743	)		—		n/a
Approved hormone therapy drug candidate patents		1,100,784		(117,993	)	$	982,791		15.75
Hormone therapy drug candidate patents (pending)		1,298,667		—			1,298,667		n/a
Non-amortizing intangible assets:
Multiple trademarks		190,940		—			190,940		indefinite
Total	$	2,714,085	$	(216,725	)	$	2,497,360

	December 31, 2016
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted- Average Remaining Amortization Period (yrs.)
Amortizing intangible assets:
OPERA® software patent	$	31,951	$	(6,490	)	$	25,461		12.75
Development costs of corporate website		91,743		(91,743	)		—		n/a
Approved hormone therapy drug candidate patents		1,093,452		(102,393	)		991,059		16
Hormone therapy drug candidate patents (pending)		1,203,987		—			1,203,987		n/a
Non-amortizing intangible assets:
Multiple trademarks		185,465					185,465		indefinite
Total	$	2,606,598	$	(200,626	)	$	2,405,972

Schedule of estimated amortization expense

Estimated amortization expense for the next five years for the patent cost currently being amortized is as follows:

Year Ending December 31,		Estimated Amortization
	2017(9 months)	$	48,297
	2018	$	64,396
	2019	$	64,396
	2020	$	64,396
	2021	$	64,396
	Thereafter	$	701,872